Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | VCSH | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Fixed Income |
52-Week High | $282.00 | $80.20 |
52-Week Low | $145.57 | $78.41 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
VCSH trades at $78.59 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with all moving averages signaling sell, though oscillators remain neutral. The ETF maintains a 4.8% yield but faces headwinds from tight credit spreads and an unattractive entry point according to recent analysis. Recent institutional activity shows mixed sentiment with both position increases and decreases.
The outlook remains cautious with limited upside potential due to current rate environment and credit spread compression. Key risks include interest rate sensitivity and competitive pressure from treasury-focused alternatives. Investors seeking short-term corporate bond exposure should monitor credit quality and duration management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
